Empty Sella: Evaluation and Management
All patients with incidentally discovered empty sella require comprehensive pituitary hormone testing at initial presentation, regardless of symptoms, as approximately 29% of incidentally discovered cases have hypopituitarism. 1
Initial Hormonal Evaluation
The 2025 Pituitary Society guidelines provide clear direction for baseline screening 1:
Measure the following hormones in all patients:
- Morning cortisol and ACTH
- Free thyroxine (T4) and TSH
- Luteinizing hormone and FSH
- IGF-1 (for growth hormone axis)
- Prolactin
- Testosterone in men; estradiol in women (premenopausal women with regular menses do not require gonadal testing)
Perform dynamic testing of the hypothalamus-pituitary-adrenal axis if morning cortisol suggests hypocortisolism. Growth hormone stimulation testing may be needed in select patients after correcting other hormone deficiencies.
Understanding the Risk Profile
The prevalence of hypopituitarism varies significantly based on how empty sella is discovered 1:
- Incidentally discovered: 29% have at least one hormone deficiency
- Clinically suspected: 40.5% have hormone deficiencies
Specific hormone deficiency rates in incidental empty sella:
- Hypocortisolism: 13.5%
- Hypothyroidism: 2.8%
- Hypogonadism: 8.5%
- Growth hormone deficiency: 12.5%
- Hyperprolactinemia: 2.9%
Risk factors predicting hypopituitarism 1:
- Male sex (P = 0.02)
- Traumatic brain injury (P = 0.003)
- Total empty sella (higher risk than partial empty sella)
Critical Clinical Pitfall
The absence of symptoms does NOT predict normal pituitary function. Studies show that symptom presence has only 71% negative predictive value for hypopituitarism 1. This is why universal hormonal screening is recommended regardless of clinical presentation.
Imaging Considerations
MRI is the gold standard for diagnosis 2. While the guidelines focus on hormonal evaluation rather than imaging surveillance for empty sella specifically, consultation with an experienced neuroradiologist is advised when there is uncertainty about the nature of the lesion 1.
Follow-Up Strategy
Repeat hormonal evaluation is indicated at 1-2 years or earlier if new clinical symptoms develop 1. This recommendation is based on evidence that progression from partial to total empty sella can be associated with hormonal deterioration (P = 0.006) 1.
If no hormonal abnormalities are detected initially, careful re-evaluation at 24-36 months is suggested given the low but present risk of progression 2.
Management of Identified Deficiencies
Patients with documented hypopituitarism should be followed according to current guidelines for those specific hormone deficiencies 1. This means:
- Hydrocortisone replacement for adrenal insufficiency
- Levothyroxine for hypothyroidism
- Sex hormone replacement for hypogonadism
- Consider growth hormone replacement in appropriate candidates
The key distinction here is that empty sella patients with confirmed deficiencies require the same rigorous hormone replacement and monitoring as patients with hypopituitarism from any other cause—this is not a "watch and wait" situation once deficiencies are identified.
Special Populations
Women with multiple pregnancies, obesity (BMI >30), and hypertension represent the classic demographic profile, with studies showing 78% parity rates and 68% overweight/obese 3. However, this demographic pattern should not influence the decision to test—all patients require evaluation.